2186:HKEXLuye Pharma Group Ltd. Analysis
Data as of 2026-09-01 - not real-time
HK$1.90
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind Luye Pharma Group Ltd. is neutral at HKD 1.90, with no clear ordering between short and long averages. It has lost 12.8% over the past 30 days. Relative strength is 36.3 — approaching oversold — and the MACD signal is bearish. Watch HKD 1.88 as support and HKD 2.32 as the nearer resistance level.
Valuation screens as undervalued: a P/E of 23.8 sits below the sector average of 30.4. Analyst price targets sit 85.6% above the current price. Revenue is growing at 4.7% on a 9.8% profit margin.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 43.9%, a beta of 0.52 and a maximum drawdown of 54.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
Valuation screens as undervalued: a P/E of 23.8 sits below the sector average of 30.4. Analyst price targets sit 85.6% above the current price. Revenue is growing at 4.7% on a 9.8% profit margin.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 43.9%, a beta of 0.52 and a maximum drawdown of 54.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
Top Market Events
In December 2017, Luye Pharma Group Ltd HKG:2186 released its most recent earnings announcement, which confirmed that...In 2003 Dian Liu was appointed CEO of Luye Pharma Group Ltd.Luye Pharma Group SEHK:2186 shares have seen moderate movement over the past month.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 2.50
- MACD momentum is negative
- 30-day price change of -12.8%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 23.8 versus sector average of 30.4
- Trading below the 200-day average of 2.50
- Analyst targets imply +85.6% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 23.8 versus sector average of 30.4
- Analyst targets imply +85.6% versus the current price
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth4.70%
Profit Margin9.81%
P/E Ratio23.8
ROE4.14%
ROA2.44%
Debt/Equity56.18
P/B Ratio0.4
Op. Cash FlowHK$1.8B
Free Cash FlowHK$-692813376
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI36.3
SupportHK$1.88
ResistanceHK$2.32
MA 20HK$2.08
MA 50HK$2.04
MA 200HK$2.50
MACDBearish
VolumeIncreasing
Fear & Greed Index93.32
Valuation
Fair ValueHK$4.16
Target PriceHK$3.53
Upside/Downside85.56%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.52
Volatility43.86%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.